Premium
Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan
Author(s) -
Jeng JenEing,
Tsai JungFa
Publication year - 1991
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890340113
Subject(s) - hepatocellular carcinoma , hbsag , medicine , hepatitis c virus , cirrhosis , gastroenterology , hepatitis b virus , antibody , hepatitis c , virus , virology , immunology
Abstract The prevalence of antibody to hepatitis C virus (anti‐HCV) was investigated in patients with hepatocellular carcinoma (HCC), and correlated with the clinical features. Anti‐HCV was detected in 129 histology or aspiration cytology proven HCC patients and 54 healthy controls. Anti‐HCV was examined by the HCV EIA (Abbott Laboratories). All healthy controls were anti‐HCV‐negative. Nineteen of 81 (23.5%) hepatitis B surface antigen (HBsAg)‐positive HCC patients were positive for anti‐HCV. Anti‐HCV was found among 60.4% (29/48) of HCC patients without detectable HBsAg. Forty‐eight of 129 (37.2%) HCC patients were positive for anti‐HCV. There was a significant difference in the prevalence of anti‐HCV between patients with HBsAg (23.5%) and those without HBsAg (60.4%, P = 0.0001). However, irrespective of the status of HBsAg, there was no statistical difference in sex, age, routine liver function tests, alpha‐fetoprotein concentration, or associated cirrhosis between patients with anti‐HCV and those without. The results imply that hepatitis C virus may play a role in the pathogenesis of HCC.